top of page

Welcome from the Co-Chairs

​TARGETING METABESITY 2022 takes on some of the most critical issues in healthcare today:

  • Focusing on chronic (not just acute) diseases

  • Shifting the spotlight beyond treatment to prevention

  • Going beyond disease-by-disease treatments to prevention of multiple diseases by addressing common root causes

  • Shifting from addressing diseases to extending healthy lifespan—healthspan

Metabesity 2022 will gather stellar speakers from multiple disciplines, including science and medicine, behavioral science, government regulation, policy, reimbursement, industry and capital markets, patient advocacy, boomer and senior lifestyle, digital health and age-technology, and many others. Expanding evidence supports that the major chronic diseases—cardiovascular and neurodegenerative diseases, diabetes, obesity, cancer, and the aging process itself—have common metabolic roots and thus may be susceptible to shared solutions. Metabesity names this constellation of conditions.

Alexander Fleming, MD, and Lawrence Steinman, MD
Targeting Metabesity 2022 Co-Chairs


Alexander Fleming, MD


Lawrence Steinman, MD

A message from Alexander Fleming, MD on Harpers Ferry and the announcement of an in-person conference next year

Meet Our Attendees

Our audience cuts across sectors and disciplines for a multi-pronged approach to one of the most important health issues affecting people in all walks of life.

  • Healthcare - Administrators, clinicians, and patient advocates interested in the prevention and delay of illness and aging

  • Preclinical Research - Scientists involved in metabolic, cancer, dementia, cardiovascular and aging-related research

  • Clinical Research - Investigators and healthcare providers involved in chronic non-communicable disease care and prevention

  • Industry -  Corporate leaders and startups that are developing pharmaceutical, digital health, nutrition, new business models and other approaches to disease prevention and healthy aging

  • Finance - Funders, payers and investors (including capital markets, philanthropies, government and insurers) in disease prevention and healthy aging

  • Policy and Law - Government regulators, policy makers, elected officials, and advisors involved in Healthspan equity and the future of Healthspan

  • Social Justice - Equity groups, social change agents, and philanthropic organizations interested in broadening access to healthy lifespan

  • ​Strategy - Futurists, epidemiologists, social scientists, economists, bioethicists, and others thinking about how to harness emerging science behind Metabesity for global public health

  • Academia - Instructors, administrators, students, and researchers across all fields of longevity, aging and Healthspan

  • Communications - Journalists and marketing professionals who recognize hot topics and emerging trends

  • The Interested Public

A message from the Co-Chairs Lawrence Steinman, MD and Alexander Fleming, MD on Metabesity 2022


“Metabesity 2021 was a fantastic opportunity to hear the absolute top people in geroscience in a highly unique format: in conversation with one another. The slide-free conversations encouraged free flowing and candid discussions that were both highly accessible to the general public and informative to a scientific audience. They were fun to watch and very educational. In the panels I participated in and those I watched, I got to hear leaders in the field thinking out loud about major challenges in research and public health and the role of geroscience in addressing them. I learned a lot and had fun too.”

-Dr. Daniel W Belsky, Assistant Professor Department of Epidemiology and Butler Columbia Aging Center, Columbia University Mailman School of Public Health

“There is absolutely no doubt that what the Kitalys Institute has achieved thus far is of incredible value for the scientific community at large. The platform that you have built has allowed, for the first time, to navigate the complicated Healthspan/Longevity space with a multidisciplinary approach, enabling silos of expertise to converge and confront in one super-connector event, the Metabesity conference. It is an absolutely rarity to find regulators sitting together with primary scientists, early, mid- and late stage biotech companies, investors, media as well as curious minds with common interest but very different approaches. The present success of Pano Therapeutics is a reflection of Kinexum and the Kitlays' support and the invaluable exposure it gave us to a growing community with the same objectives but alternate viewpoints. Moreover, the dedicated webinar around mitochondria and healthy aging that the Kitalys organized early this year has unveiled our core technology and science to a broader audience and skyrocketed our R&D development around mitochondrial therapeutics that address aging. It has been amazing to us and it will be, I am sure, to future companies interested at joining the Kitalys and its events. We learnt a great deal and we are confident there is much more to come.
-Pano Therapeutics

“I thoroughly enjoyed the 2021 program.  The renowned individuals that led the sessions, that presented and the lovely format of “chat” with experts was terrific.  It was a breath of fresh air to hear discussions of topics that are rarely discussed as there is so much out there that the average health care professional is not privy to.  I was not able to fully participate in the games and development descriptions of the last couple of days but it was so inventive to have designed these.  I loved the visual and auditory (great music) pleasures during intermissions! Overall, it was enlightening, supports my ongoing research into aging, longevity, metabesity and the entire concept of cardiometabolic disease.  Thank you for all your efforts.”
-Lois Love Exelbert RN, MS, CDCES, BC-ADM, LCCE, Manager Diabetes Care Center Baptist Hospital of Miami

“I truly believe that the very different perspectives and backgrounds of the speakers were useful to trigger discussions. The point that Antonio and Ed finished on was key; i.e. how to evolve value propositions for consumers beyond “health”. Being in better physiological condition is certainly not enough as incentive. If it were enough,  we would have much less non-communicable diseases in this world. For large FMCG companies, evolving value propositions is the bread and butter. However, there is much to learn how to bring breakthrough innovation for prevention and age reversal into attractive commercial models that work from super premium to mass markets. Thanks all for the fruitful panel discussions.”

-Dr. Philipp Gut, Department Head at Nestlé Institute of Health Sciences, Nestlé Research, Switzerland and Principal Investigator Healthy Aging and Cellular Nutrition

“My personal sincere thanks to everyone who participated on this panel.  The time indeed did fly by and I really enjoyed both the individual perspectives and the group discussion. Thanks again to the exceptional Kinexum/Kitalys team for, once again, pulling together such a superb forward-looking and thought-provoking program.”

-Ed Saltzman, Executive Chairman, Cello Health BioConsulting

bottom of page